Entries by Georg Kääb

How to build on Europe’s strengths

The region regulated by the European Medicines Agency (EMA) has been the most proactive globally in the early adoption of biosimilars. By February 2023, it had approved around 75 products containing them. The distribution of such compounds within Europe, however, has been uneven, with some countries offering more market opportunities than others. Beyond Europe, few producers have a strategy for the Middle East and/or Africa, and India and South Korea could soon jump in to fill the gap.

Spatial Biology Company Navinci (Olink) closes EUR9m Series A

Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration, a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.

Novo Nordisk snatches Dicerna

Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.

Investors pool €27m for new Proteomics tech

UK-based biotech startup Fluidic Analytics has raised €27m for its proteomics platform. The financing round was led by Draper Esprit, with participation from Delin Ventures, BGF, IQ Capital, and Amadeus Capital Partners.